Aarey Drugs & Pharmaceuticals Limited is an Indian-listed entity primarily engaged in the manufacturing of **Active Pharmaceutical Ingredients (APIs)** and the large-scale trading of industrial chemicals. The company operates a dual-model business that integrates manufacturing with import-based distribution to serve a wide array of industrial applications, ranging from healthcare to heavy industry. --- ### **Core Business Verticals & Product Portfolio** The company operates through a single reportable segment: **Manufacturing and Trading of Drugs & Pharmaceuticals**. However, its operational mandate is highly diversified, covering several industrial pillars: #### **1. Pharmaceutical Manufacturing (APIs & Intermediates)** The company produces critical bulk drugs and intermediates with a focus on high-demand therapeutic areas: * **Key APIs:** Metformin HCL, Mefenamic Acid, Doxophylline, and Theophylline. * **Intermediates:** Mono Methyl Urea, Die Methyl Urea, Uracile, DMA-HCL, and Ortho chloro benzoic acid. * **Healthcare & Hygiene:** Production of surgical cotton, bandages, tapes, cosmetics, and toiletries. Notably, the company utilizes **waste material** generated during primary manufacturing to produce hygiene products. #### **2. Industrial Chemical Trading & Imports** Aarey acts as a major importer and dealer of **Solvents & Chemicals**, serving sectors such as polymers, pigments, and oils. * **Chemical Range:** Heavy and fine chemicals, organic/inorganic alkalies, and petrochemicals. * **Paints & Coatings:** Oil and color paints, lacquers, enamels, varnishes, and turpentine. #### **3. Diversified Industrial Mandate** Beyond its core pharma operations, the company maintains the capacity and regulatory mandate to operate in: * **Paper & Pulp:** Writing, printing, craft, and specialized papers (lithmus, insulating, and photographic papers). * **Packaging:** Corrugated boxes, multi-layer laminates, and molded plastic articles (PVC, polystyrene, polyurethane). * **Agri-Business:** Vegetable oils, dairy products, poultry farming, and cold storage for tea, coffee, and rubber. * **Explosives:** Safety fuses and accessories for military and mining applications. --- ### **Operational Infrastructure & Efficiency** The company’s operations are centralized in Maharashtra, focusing on technical efficiency and asset management. * **Manufacturing Base:** Located at **E-34, M.I.D.C., Tarapur, Boisar, District Palghar**. * **Energy Management:** The facility utilizes a **Dual Fuel Burner** and automated feed regulators for grinding, maintaining a high power factor above **0.9**. * **Corporate Presence:** Headquartered in **Masjid, Mumbai**, with a registered office at the Tarapur factory site. * **Asset Status:** Management conducts regular physical verification of **Property, Plant and Equipment (PPE)**. As of recent audits, the company holds no **Intangible Assets**. --- ### **Financial Performance & Capital Structure** Aarey Drugs maintains a cautious funding strategy, relying on internal cash delivery and strategic equity infusions rather than heavy debt. #### **Comparative Financial Summary** | Particulars (₹ in Lakhs) | FY 2022-23 | FY 2021-22 | | :--- | :--- | :--- | | **Total Income** | **42,168.56** | **49,542.75** | | **Total Expenditure** | **41,567.59** | **48,539.05** | | **Profit Before Tax (PBT)** | **600.96** | **1,003.71** | | **Profit After Tax (PAT)** | **377.11** | **655.48** | #### **Key Corporate Data** | Metric | Details | | :--- | :--- | | **Listing Status** | Listed on **BSE (524412)** and **NSE (AAREYDRUGS)** | | **Credit Rating (FY24)** | **ACUITE BBB / Stable** | | **Promoter Holding** | **45.44%** (as of Dec 2024) | | **Total Share Capital** | **2,84,54,303** shares (as of Sep 2025) | | **Authorised Capital** | **₹35.50 Crores** (3.55 Crore Equity Shares) | --- ### **Strategic Growth & Capital Infusion** The company is executing a multi-phase expansion strategy funded through preferential allotments to both promoters and non-promoters. * **Fundraising Objectives:** Proceeds are directed toward **factory unit expansion**, the restructuring or settlement of existing bank liabilities, and **investments in technology** to enhance manufacturing competitiveness. * **Recent Allotments:** * **May 2025:** Allotted **50,00,000 Convertible Warrants** at **₹63.80** per warrant. * **March 2024:** Allotted **26,69,619 Equity Shares** at **₹37.80** and **6,00,000 Warrants** at **₹47.80**. * **August 2023:** Issued **50,00,000 Equity Shares** at **₹36.10**, raising approximately **₹18.05 Crores**. * **Expansion Limits:** Shareholders have approved borrowing limits up to **₹300 Crores** and investment/loan limits up to **₹300 Crores** to support the broader business ecosystem. * **Integration Strategy:** The company is pursuing **backward and forward integration** for products like **DMA-HCL** and **Theophylline** to improve margins. --- ### **Risk Management & Compliance Profile** Aarey Drugs operates under a formal **Vigil Mechanism** and **IND AS 108** compliance, though it faces specific historical and operational risks. #### **Financial & Market Risks** * **Credit Risk:** Managed through customer creditworthiness monitoring. Trade receivables stood at **₹18,447.77 Lakhs** (March 2024), with **₹1,987.24 Lakhs** aged over **180 days**. * **Liquidity Risk:** The company maintains a **positive cash balance** and utilizes rolling forecasts to ensure working capital sufficiency. * **Market Risk:** Exposure to foreign exchange and commodity price risk was reported as **immaterial** in recent cycles. #### **Regulatory & Governance Challenges** * **Compliance Observations:** The company has faced scrutiny from **BSE/NSE** regarding delays in listing preferential shares and failure to strictly follow **SEBI (ICDR) Regulations, 2018**. * **Share Discrepancy:** A discrepancy of **1,00,000 shares** exists between company books and **RTA** records due to withheld listing approvals for a specific allottee (**Watco Chennai Real Estate Pvt Ltd**). * **Administrative Lapses:** Past penalties include **₹1,88,800** for RPT filing errors and historical non-compliance with **SEBI (Prohibition of Insider Trading)** regulations, though a **Structured Digital Database (SDD)** has now been implemented. * **Asset Utilization:** Auditors have highlighted **Plant and Machinery** that was added to the Fixed Asset Schedule but was **not yet in a state to be used**; depreciation will impact future profitability once these assets are commissioned.